Galectin 10 antibody (AA 2-142) (HRP)

Catalog No. ABIN7153447

This anti-Galectin 10 antibody is a Rabbit Polyclonal antibody detecting Galectin 10 in ELISA. Suitable for Human.

Quick Overview for Galectin 10 antibody (AA 2-142) (HRP) (ABIN7153447)

Target: Galectin 10 (CLC) (Charcot-Leyden Crystal Protein (CLC))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Galectin 10 antibody is conjugated to HRP

Application: ELISA

Product Details anti-Galectin 10 Antibody (HRP)

Binding Specificity: AA 2-142

Purpose: CLC Antibody, HRP conjugated

Purification: Protein G purified

Purity: >95 %

Immunogen: Recombinant Human Galectin-10 protein (2-142AA)

Isotype: IgG

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Details for Galectin 10

Target: Galectin 10 (CLC) (Charcot-Leyden Crystal Protein (CLC))

Alternative Name: CLC

Background:

Background: Regulates immune responses through the recognition of cell-surface glycans. Essential for the anergy and suppressive function of CD25-positive regulatory T-cells (Treg).

Aliases: BSF3 antibody, Charcot Leyden crystal protein antibody, Charcot-Leyden crystal protein antibody, CLC antibody, EC 3.1.1.5 antibody, Eosinophil lysophospholipase antibody, Gal-10 antibody, Galectin-10 antibody, LGALS10 antibody, LGALS10A antibody, LPPL HUMAN antibody, LPPL_HUMAN antibody, Lysolecithin acylhydrolase antibody, MGC149659 antibody

UniProt: Q05315

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response